Public Health Link om the Chief Medical Officer for Wales

Distribution:	As Appendix 2	
From:	Chief Pharmaceutical Officer, Andrew Evans	
Date:	30 July 2019	
Reference:	CEM/CPhA/2019/20	
Category:	Class 2 - Action within 48 hours	
Title:	Drug Alert Class 2, Action Within 48 Hours, Accord-Uk Ltd In Actavis Livery, Aripiprazole 1mg/Ml Oral Solution	
For Action by:		
seen by all	General Practitioners – please ensure this message is working in your dispensary and retain a copy in your mation pack'	

Community Pharmacists

Hospital pharmacies

Chief Pharmacists

For Information:	See Annex 2 – Distribution List
What is this about:	Full details are set out below.
Why has it been sent:	For your information, action and to pass on to colleagues.

Issue:

Accord-UK Ltd is recalling some batches of the above product because there is the potential for small particles of Aripiprazole active substance to be present.

Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts

Appendix 1

To: Chief Executives of Health Boards and NHS Trusts

To: Medical Directors of Health Boards

To: Nurse Directors Health Boards

To: Directors of Public Health

To: Hospital Principals and Chief Pharmacists to action as per alert

To: NHS Wales Shared Services Partnership to forward to:

Dispensing General Practitioners

Community Pharmacists

Deputising services

HB Prescribing Advisers

Independent/Private clinics and Hospitals and Hospices throughout Wales





DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours Pharmacy Level Recall

Date: 30 July 2019

EL (19)A/20

Our Ref: MDR 84-07/19

Dear Healthcare Professional,

Accord-UK Ltd in Actavis Livery

Aripiprazole 1mg/ml oral solution

PL 0142/0901

Batch Number	Expiry Date	Pack Size	First Distributed
080618	06/2020	150ml	08 Aug 2018
090618	06/2020	150ml	03 Sept 2018

Brief description of problem

Accord-UK Ltd is recalling the above batches due to the potential for small particles of Aripiprazole active material to be present which may affect the efficacy of the product. No relevant product complaints or adverse reaction reports have been received by the company from the UK market to date.

Advice for Healthcare Professionals and Wholesalers

Stop supplying the batches listed above immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Company contacts for further information

For stock control enquiries please contact Accord-UK Ltd Customer Services Team on 0800 373573

For medical information enquiries please contact Accord-UK Ltd Medical Information Department on 01271 385257

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS Regional teams are asked to forward this to relevant clinics, general practitioners and community pharmacists.

Yours faithfully

Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574